Varicose vein ablation and sclerotherapy
Ablation and sclerotherapy are procedures that close a vein that has reflux, which is blood flowing backward in the vein. A 2025 review says the main goal of treating venous insufficiency is to close the superficial veins that have reflux. It divides the catheter-based methods into thermal ablation, which uses radiofrequency or laser energy, and non-thermal, non-tumescent ablation, which is chemical, mechanochemical or adhesive. In sclerotherapy a chemical injected into the vein damages its lining, leading to scarring and closure; MeSH describes it as injection or infusion of chemical agents that cause localized thrombosis and eventual fibrosis and obliteration of the vessels. The US labels of two polidocanol medicines are cited for their indication wording only. The Varithena (polidocanol injectable foam) label names "incompetent great saphenous veins, accessory saphenous veins" and "visible varicosities of the great saphenous vein (GSV) system above and below the knee". The Asclera label says it is indicated to sclerose "uncomplicated spider veins (varicose veins ≤1 mm in diameter)" and "uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter)" in the lower extremity. The review says non-thermal methods had better quality of life scores but lower primary closure rates than thermal ablation. A 2026 meta-analysis of 23 trials (3,122 patients) compared foam sclerotherapy with high ligation and stripping surgery for great saphenous vein reflux and found a lower occlusion rate with foam, with low overall certainty. This page gives no advice on who should have which procedure.
Also called Endovenous ablation · Sclerotherapy · Foam sclerotherapy
- Intervention
- In this atlas
Overview
Technical summary
Strategy page. MeSH descriptor D015911 (Sclerotherapy) is a broad match: its scope note also covers hemorrhoids, gastric and esophageal varices and ulcer bleeding, and thermal ablation is not sclerotherapy. The 2025 review (Current Cardiology Reports) lists common complications of sclerotherapy as hyperpigmentation, telangiectatic matting, pain and urticaria. The 2026 meta-analysis (Frontiers in Medicine) pooled randomized trials only. The labels were read through openFDA on 2026-11-18 (Varithena label effective 2026-10-07, Asclera label effective 2025-07-16); openFDA says its data are unvalidated and not for medical decisions. This page states no recommendation of when to use either approach, and quotes no doses.
About this intervention
- Type
- Procedure
- Mechanism
- Thermal ablation closes a refluxing vein with radiofrequency or laser energy; sclerotherapy uses a chemical agent that damages the vein lining and leads to fibrosis and closure (an open-access review).
Classification codes
-
D015911
Claims and evidence
No claims are published for this intervention yet.
Record details
- Record id
cardio:varicose-vein-ablation-and-sclerotherapy- Content hash
0438fa920b4229492478aa89cb4877a01cb414e6420d25674a4a6356bf9d52ab